[go: up one dir, main page]

KR950703988A - 긴 보장기간을 갖는 g-csf의 수성 약제 조성물(aqueous pharmaceutical preparations of g-csf whth a long shelf life) - Google Patents

긴 보장기간을 갖는 g-csf의 수성 약제 조성물(aqueous pharmaceutical preparations of g-csf whth a long shelf life)

Info

Publication number
KR950703988A
KR950703988A KR1019950702589A KR19950702589A KR950703988A KR 950703988 A KR950703988 A KR 950703988A KR 1019950702589 A KR1019950702589 A KR 1019950702589A KR 19950702589 A KR19950702589 A KR 19950702589A KR 950703988 A KR950703988 A KR 950703988A
Authority
KR
South Korea
Prior art keywords
solution
value
composition according
acid
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019950702589A
Other languages
English (en)
Other versions
KR100266146B1 (ko
Inventor
미하엘리스 우베
루돌프 라이너
빈터 게르하르트
보오크 하인리히
Original Assignee
헤르베르트 포우퀘트·라인홀트 밍크
뵈링거 만하임 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6475732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR950703988(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 헤르베르트 포우퀘트·라인홀트 밍크, 뵈링거 만하임 게엠베하 filed Critical 헤르베르트 포우퀘트·라인홀트 밍크
Publication of KR950703988A publication Critical patent/KR950703988A/ko
Application granted granted Critical
Publication of KR100266146B1 publication Critical patent/KR100266146B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 아세트산, 락트산, 시트르산, 말레산, 인산 및 이것들의 염 또는 아르기닌 및 이것의 염으로 구성된 군으로부터 선택된 하나 이상의 완충제를 100mmol/1 이하의 농도로 함유하고 저장시에 안정한, G-CSF를 함유하는 수성 약제 조성물에 관한 것이다.

Description

긴 보장기간을 갖는 G-CSF의 수성 약제 조성물(AQUEOUS PHARMACEUTICAL PREPARATIONS OF G-CSF WITH A LONG SHELF LIFE)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도 내지 4도는 각각 완충계에 대한 pH 혼탁도 곡선이다.

Claims (15)

  1. 치료적으로 유효량의 G-CSF, 및 아세트산, 락트산, 시트르산, 말레산, 인산 및 이것들의 염 또는 아르기닌 및 이것의 염으로 구성된 군으로부터 선택된 하나 이상의 완충 성분을 함유하며, 투여용 용액중의 완충제 성분의 최종 농도가 2 내지 100mmo1/1인 안정한 수성 약제 조성물.
  2. 제1항에 있어서, 인산염의 농도가 5 내지 80mmo1/1이고, 투여용 용액의 값이 pH값이 3.5 내지 5 또는 7 내지 8의 값으로 조절됨을 특징으로 하는 조성물.
  3. 제1항에 있어서, 시트르산염의 농도 또는 말레산염의 농도가 5 내지 40mmo1/1이고, 용액의 pH값이 2.5 내지 3.5 또는 7 내지 8의 값으로 조절됨을 특징으로 하는 조성물.
  4. 제1항에 있어서, 완충성분으로서 인산염 및 시트르산염의 전체 농도가 5 내지 40mmo1/1이고, 용액의 pH값이 2.5 내지 3.5 또는 7 내지 8의 값으로 조절됨을 특징으로 하는 조성물.
  5. 제1항에 있어서, 아세트산염의 농도 또는 락트산염의 농도가 5 내지 80mmo1/1이고, 용액의 pH값이 3.5 내지 5의 값으로 조절됨을 특징으로 하는 조성물.
  6. 제1항에 있어서, 인산 아르기닌, 염화 아르기닌, 시트르산 아르기닌 완충제의 농도가 5내지 80mmo1/1이고, 용액의 pH값이 7 내지 8의 값으로 조절됨을 특징으로 하는 조성물.
  7. 제1항 내지 6항중 어느 한 항에 있어서, 용액이 사용되는 G-CSF의 양 이하의 계면활성제를 함유함을 특징으로 하는 조성물.
  8. 제7항에 있어서, 용액이 0.5㎎/㎖ 이하, 바람직하게는 0.01 내지 0.1㎎/㎖의 계면활성제률 함유함을 특징으로 하는 조성물.
  9. 제1항 내지 8항중 어느 한 항에 있어서, 용액이 통상적인 보조성분 또는 동등한 제제를 더 함유함을 특징으로 하는 조성물.
  10. 제1항 내지 9항중 어느 한 항에 있어서, 용액이 중합체 또는 단백질-형 보조성분을 함유하지 않음을 특징으로 하는 조성물.
  11. 치료적으로 유효량의 G-CSF를, 투여용 용액중의 완충제 성분의 최종 농도가 2 내지 100mmo1/1이 될 정도로 선택된 양의 아세트산, 락트산, 시트르산. 말레산, 인산 및 이것들의 염 또는 아르기닌 및 이것의 염으로 구성된 군으로부터 선택된 하나 이상의 완충제 성분과 혼합시키는 것으로 이루어지는, G-CSF률 함유하는 안정한 약제 조성물의 제조방법.
  12. 안정화제로서 아세트산, 락트산, 시트르산, 말레산, 인산 및 이것들의 염 또는 아르기닌 및 이것의 염으로 구성된 군으로부터 선택된 하나 이상의 완충제 성분이 투여용 용액중에서 2 내지 100mmo1/1의 최종 농도로 사용되어 혼탁성을 방지하는 것으로 이루어지는, G-CSF를 함유하는 약제 조성물을 안정화시키기 위한 방법.
  13. G-CSF를 함유하는 약제 조성물의 경우에 혼탁성을 방지하기 위한 아세트산, 락트산, 시트르산, 말레산, 인산 및 이것들의 염 또는 아르기닌 및 이것의 염의 사용방법.
  14. 제1항 내지 10항중 어느 한 항에 따르는 조성물로부터 생성되는 동결건조물 또는 분말.
  15. 물 또는 수용액중에 재13항에 따르는 동결건조물 또는 분말을 용해시킴으로써 생성되는, 제1항 내지 10항중 어느 한 항에 따르는 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950702589A 1992-12-18 1993-12-15 긴 보장기간을 갖는 g-csf의 수성 약제 조성물 Expired - Fee Related KR100266146B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP4242919.6 1992-12-18
DE4242919A DE4242919A1 (de) 1992-12-18 1992-12-18 Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
PCT/EP1993/003544 WO1994014466A1 (de) 1992-12-18 1993-12-15 Lagerstabile wässrige pharmazeutische zubereitungen von g-csf

Publications (2)

Publication Number Publication Date
KR950703988A true KR950703988A (ko) 1995-11-17
KR100266146B1 KR100266146B1 (ko) 2000-09-15

Family

ID=6475732

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950702589A Expired - Fee Related KR100266146B1 (ko) 1992-12-18 1993-12-15 긴 보장기간을 갖는 g-csf의 수성 약제 조성물

Country Status (11)

Country Link
US (1) US5919757A (ko)
EP (1) EP0674525B1 (ko)
JP (1) JPH08505610A (ko)
KR (1) KR100266146B1 (ko)
AT (1) ATE203411T1 (ko)
AU (1) AU692430C (ko)
CA (1) CA2151957C (ko)
DE (2) DE4242919A1 (ko)
HU (1) HU219548B (ko)
NZ (1) NZ259333A (ko)
WO (1) WO1994014466A1 (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
WO1996024369A1 (en) * 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
AUPO624797A0 (en) * 1997-04-17 1997-05-15 Amcor Limited A tamper indicating closure
KR100389726B1 (ko) * 1998-03-06 2003-06-27 쥬가이 세이야쿠 가부시키가이샤 안정한 과립구 콜로니-자극 인자 함유 제제
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
EP0988861B1 (en) * 1998-08-17 2004-03-03 Pfizer Products Inc. Stabilized protein compositions
EP1025861A1 (de) * 1999-02-04 2000-08-09 Roche Diagnostics GmbH Pharmazeutische Zusammensetzung von hydrophob modifizierten Hedgehog-Proteinen und deren Verwendung
WO2000051626A1 (fr) * 1999-03-01 2000-09-08 Kyowa Hakko Kogyo Co., Ltd. Preparations de g-csf modifiees chimiquement
ATE269716T1 (de) * 2000-02-29 2004-07-15 Pfizer Prod Inc Stabilisierter granulozyten-kolonie- stimulierender faktor
AUPQ633900A0 (en) 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
KR20030027077A (ko) * 2000-09-01 2003-04-03 쥬가이 세이야쿠 가부시키가이샤 장기 안정화 용액 제제
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US7807406B2 (en) 2002-05-09 2010-10-05 Cornell Research Foundation, Inc. Fagopyritol synthase genes and uses thereof
CA2530531A1 (en) * 2003-06-30 2005-01-20 Alza Corporation Formulations for coated microprojections containing non-volatile counterions
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
DK1682074T3 (da) 2003-10-24 2012-05-29 Nora Therapeutics Inc Præparater og fremgangsmåder til sund graviditet
US7585496B2 (en) * 2003-11-04 2009-09-08 Lek Pharmaceuticals D.D. Stable pharmaceutical composition granulocyte-colony stimulating factor
KR100978717B1 (ko) 2003-12-08 2010-08-30 씨펙스 파마슈티칼스, 인코포레이티드 인슐린 치료를 위한 약제 조성물 및 방법
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
DE102006009437A1 (de) * 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
DE202007018629U1 (de) 2007-08-27 2008-12-24 Biogenerix Ag Flüssigformulierung von G-CSF
AU2008291309B2 (en) 2007-08-27 2013-10-17 Ratiopharm Gmbh Liquid formulation of G-CSF
TWI409082B (zh) * 2010-01-19 2013-09-21 Hanmi Science Co Ltd 用於長效型粒細胞集落刺激因子（ｇ－ｃｓｆ）共軛物之液態劑型
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
HUP1200172A2 (en) * 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
WO2015057724A1 (en) 2013-10-14 2015-04-23 Nora Therapeutics, Inc. Use of g-csf for treating or preventing villitis of unknown etiology in a human female
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
CN104906053B (zh) * 2015-06-12 2018-01-16 北京四环生物制药有限公司 注射用重组人粒细胞刺激因子冻干粉针剂
CN112121009B (zh) * 2020-09-24 2022-12-02 科兴生物制药股份有限公司 一种聚乙二醇修饰重组人粒细胞刺激因子新制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JPH0477434A (ja) * 1990-07-17 1992-03-11 Kanji Takada 顆粒球コロニー刺激因子の眼粘膜適用製剤
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke

Also Published As

Publication number Publication date
US5919757A (en) 1999-07-06
DE4242919A1 (de) 1994-06-23
DE59310197D1 (de) 2001-08-30
HUT74270A (en) 1996-11-28
HU9501767D0 (en) 1995-08-28
KR100266146B1 (ko) 2000-09-15
AU5810994A (en) 1994-07-19
AU692430B2 (en) 1998-06-11
HU219548B (hu) 2001-05-28
EP0674525A1 (de) 1995-10-04
JPH08505610A (ja) 1996-06-18
AU692430C (en) 2007-09-20
CA2151957C (en) 2008-02-12
NZ259333A (en) 1996-10-28
EP0674525B1 (de) 2001-07-25
ATE203411T1 (de) 2001-08-15
WO1994014466A1 (de) 1994-07-07
CA2151957A1 (en) 1994-07-07

Similar Documents

Publication Publication Date Title
KR950703988A (ko) 긴 보장기간을 갖는 g-csf의 수성 약제 조성물(aqueous pharmaceutical preparations of g-csf whth a long shelf life)
US4931441A (en) Stabilized aqueous leucovorin calcium compositions
US4647454A (en) Stable interferon β composition and a method of stabilizing interferon β
US2795529A (en) Stabilized hyaluronidase solution containing calcium chloride
US4244943A (en) Method for preparing urokinase injection
FI78837C (fi) Foerfarande foer framstaellning av en foer injektionsadministration laemplig, stabil och saltsyrahaltig vattenloesning av cis-platina.
KR890012634A (ko) 제약 조성물의 안정성을 개선시키는 방법
KR890015745A (ko) 수용액으로 존재하는 피록시캄의 제약 조성물 및 그의 제조방법
US3940480A (en) Process for production of stabilized powdery secretin preparation by lyophilization
KR930000096A (ko) 제제
CA2405378C (en) Stable taurolidine electrolyte solutions
EP0048944B1 (en) An antimicrobial preparation
AU684350B2 (en) Stable aqueous folinate solution
US2407412A (en) Therapeutic solutions
US3767803A (en) Stable aqueous pyritinol solutions
CA2015632A1 (en) Stable solutions of rebeccamycin analog and preparations thereof
US2920015A (en) Long-acting vitamin b12
US4954522A (en) Lyophilized preparation of platinum compound
US2388261A (en) Riboflavin solution
JPH0129170B2 (ko)
JPH0418032A (ja) 組織プラスミノーゲンアクチベーター若しくはその誘導体を含有する血栓溶解剤
NO175565B (no) Fremgangsmåte for fremstilling av et parenteralt anvendbart, farmasöytisk preparat inneholdende et bis-indolalkaloid
US4579960A (en) Stable solutions containing thimerosal
US2720482A (en) Stabilized streptomycin solutions
US3004891A (en) Stable, aqueous solutions of sodium phosphite, sodium formaldehyde sulfoxylate, and dihydrostreptomycin sulfate

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20030622

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20030622

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000